One study reported that the expression of SGK1 is decreased in the brain of AD patients and that SGK1 can promote nonamyloidogenic APP processing and Aβ degradation as well as upregulate the expression of synaptic plasticity‐related proteins, playing a notable role in the treatment of AD memory disorder.13 The gene discussed is APP; the disease is Alzheimer disease.